Literature DB >> 26179759

T cells compete by cleaving cell surface CD27 and blocking access to CD70-bearing APCs.

Matthew A Burchill1, Beth A Tamburini1, Ross M Kedl1.   

Abstract

T cells compete against each other for access to molecules on APCs in addition to peptide/MHC complexes. However, the identity of cell surface molecules that influence T-cell competition, other than peptide/MHC, have yet to be defined. Here, we identify CD70, a TNF ligand expressed on activated APCs, as an important mediator of T-cell competition for APCs. Upon engagement of CD27 by CD70, CD27 is proteolytically cleaved from the surface of the interacting CD8(+) T cell and captured by CD70 expressing dendritic cells. The capture of CD27 effectively masks CD70 on APCs, disallowing the interaction with CD27 on other competing T cells. Collectively, our data indicate that T cells compete against each other for access to the TNF-ligand CD70, an interaction that affects the duration and potency of T cell/DC interactions, thus influencing the repertoire of responding CD8(+) T cells to self or foreign antigens.
© 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  CD27; CD70; CD8 T cell; Competition; Dendritic cell

Mesh:

Substances:

Year:  2015        PMID: 26179759      PMCID: PMC4674305          DOI: 10.1002/eji.201545749

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  44 in total

1.  Agonist anti-human CD27 monoclonal antibody induces T cell activation and tumor immunity in human CD27-transgenic mice.

Authors:  Li-Zhen He; Naseem Prostak; Lawrence J Thomas; Laura Vitale; Jeffrey Weidlick; Andrea Crocker; Catherine D Pilsmaker; Sarah M Round; Alison Tutt; Martin J Glennie; Henry Marsh; Tibor Keler
Journal:  J Immunol       Date:  2013-09-11       Impact factor: 5.422

2.  Combined TLR/CD40 stimulation mediates potent cellular immunity by regulating dendritic cell expression of CD70 in vivo.

Authors:  Phillip J Sanchez; Jennifer A McWilliams; Catherine Haluszczak; Hideo Yagita; Ross M Kedl
Journal:  J Immunol       Date:  2007-02-01       Impact factor: 5.422

3.  Metalloprotease inhibitors block release of soluble CD27 and enhance the immune stimulatory activity of chronic lymphocytic leukemia cells.

Authors:  Kazunori Kato; Peter Chu; Satoshi Takahashi; Hirofumi Hamada; Thomas J Kipps
Journal:  Exp Hematol       Date:  2007-03       Impact factor: 3.084

4.  The costimulatory molecule CD27 maintains clonally diverse CD8(+) T cell responses of low antigen affinity to protect against viral variants.

Authors:  Klaas P J M van Gisbergen; Paul L Klarenbeek; Natasja A M Kragten; Peter-Paul A Unger; Marieke B B Nieuwenhuis; Felix M Wensveen; Anja ten Brinke; Paul P Tak; Eric Eldering; Martijn A Nolte; Rene A W van Lier
Journal:  Immunity       Date:  2011-07-14       Impact factor: 31.745

5.  Aberrant expression of CD27 and soluble CD27 (sCD27) in HIV infection and in AIDS-associated lymphoma.

Authors:  D Widney; G Gundapp; J W Said; M van der Meijden; B Bonavida; A Demidem; C Trevisan; J Taylor; R Detels; O Martínez-Maza
Journal:  Clin Immunol       Date:  1999-11       Impact factor: 3.969

6.  CD70 is downregulated by interaction with CD27.

Authors:  Mirela Kuka; Ivana Munitic; Maria Letizia Giardino Torchia; Jonathan D Ashwell
Journal:  J Immunol       Date:  2013-08-02       Impact factor: 5.422

7.  The CD27 membrane receptor, a lymphocyte-specific member of the nerve growth factor receptor family, gives rise to a soluble form by protein processing that does not involve receptor endocytosis.

Authors:  W A Loenen; E De Vries; L A Gravestein; R Q Hintzen; R A Van Lier; J Borst
Journal:  Eur J Immunol       Date:  1992-02       Impact factor: 5.532

8.  Phenotype and function of protective, CD4-independent CD8 T cell memory.

Authors:  Lindsay E Edwards; Catherine Haluszczak; Ross M Kedl
Journal:  Immunol Res       Date:  2013-03       Impact factor: 2.829

9.  Development of a human monoclonal antibody for potential therapy of CD27-expressing lymphoma and leukemia.

Authors:  Laura A Vitale; Li-Zhen He; Lawrence J Thomas; Jennifer Widger; Jeffrey Weidlick; Andrea Crocker; Thomas O'Neill; James Storey; Martin J Glennie; Deanna M Grote; Stephen M Ansell; Henry Marsh; Tibor Keler
Journal:  Clin Cancer Res       Date:  2012-05-15       Impact factor: 12.531

10.  Complete but curtailed T-cell response to very low-affinity antigen.

Authors:  Dietmar Zehn; Sarah Y Lee; Michael J Bevan
Journal:  Nature       Date:  2009-01-28       Impact factor: 49.962

View more
  10 in total

Review 1.  Stimulating CD27 to quantitatively and qualitatively shape adaptive immunity to cancer.

Authors:  Timothy Nj Bullock
Journal:  Curr Opin Immunol       Date:  2017-03-17       Impact factor: 7.486

Review 2.  CD4 T cells in protection from influenza virus: Viral antigen specificity and functional potential.

Authors:  Andrea J Sant; Anthony T DiPiazza; Jennifer L Nayak; Ajitanuj Rattan; Katherine A Richards
Journal:  Immunol Rev       Date:  2018-07       Impact factor: 12.988

3.  Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia.

Authors:  Mark B Leick; Harrison Silva; Irene Scarfò; Rebecca Larson; Bryan D Choi; Amanda A Bouffard; Kathleen Gallagher; Andrea Schmidts; Stefanie R Bailey; Michael C Kann; Max Jan; Marc Wehrli; Korneel Grauwet; Nora Horick; Matthew J Frigault; Marcela V Maus
Journal:  Cancer Cell       Date:  2022-04-21       Impact factor: 38.585

4.  Generating a Tolerogenic Cell Therapy Knowledge Graph from Literature.

Authors:  Andre Lamurias; João D Ferreira; Luka A Clarke; Francisco M Couto
Journal:  Front Immunol       Date:  2017-11-29       Impact factor: 7.561

5.  Construction of a Prognostic Immune-Related LncRNA Risk Model for Lung Adenocarcinoma.

Authors:  Yue Li; Ruoyi Shen; Anqi Wang; Jian Zhao; Jieqi Zhou; Weijie Zhang; Ruochen Zhang; Jianjie Zhu; Zeyi Liu; Jian-An Huang
Journal:  Front Cell Dev Biol       Date:  2021-03-18

6.  Monitoring Circulating Immune Checkpoint Proteins as Predictors of Non-AIDS Morbid Events in People With HIV Initiating Antiretroviral Therapy.

Authors:  Thomas A Premeaux; Carlee B Moser; Ashley McKhann; Martin Hoenigl; Stephen T Yeung; Alina P S Pang; Michael J Corley; Michael M Lederman; Alan L Landay; Sara Gianella; Lishomwa C Ndhlovu
Journal:  Open Forum Infect Dis       Date:  2022-01-21       Impact factor: 4.423

7.  Hypoxia-Inducible Factor-2 Alpha Regulates the Migration of Fibroblast-like Synoviocytes via Oxidative Stress-Induced CD70 Expression in Patients with Rheumatoid Arthritis.

Authors:  Su-Jin Yoo; Ha-Reum Lee; Jinhyun Kim; In Seol Yoo; Chan Keol Park; Seong Wook Kang
Journal:  Int J Mol Sci       Date:  2022-02-20       Impact factor: 5.923

8.  Single agent BMS-911543 Jak2 inhibitor has distinct inhibitory effects on STAT5 signaling in genetically engineered mice with pancreatic cancer.

Authors:  Thomas A Mace; Reena Shakya; Omar Elnaggar; Kristin Wilson; Hannah M Komar; Jennifer Yang; Jason R Pitarresi; Gregory S Young; Michael C Ostrowski; Thomas Ludwig; Tanios Bekaii-Saab; Mark Bloomston; Gregory B Lesinski
Journal:  Oncotarget       Date:  2015-12-29

9.  The Effect of Vector Silencing during Picornavirus Vaccination against Experimental Melanoma and Glioma.

Authors:  Courtney S Malo; Danielle N Renner; April M Huseby Kelcher; Fang Jin; Michael J Hansen; Kevin D Pavelko; Aaron J Johnson
Journal:  PLoS One       Date:  2016-08-25       Impact factor: 3.240

10.  PD-L1 Reverse Signaling in Dermal Dendritic Cells Promotes Dendritic Cell Migration Required for Skin Immunity.

Authors:  Erin D Lucas; Johnathon B Schafer; Jennifer Matsuda; Madison Kraus; Matthew A Burchill; Beth A Jirón Tamburini
Journal:  Cell Rep       Date:  2020-10-13       Impact factor: 9.423

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.